These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 798201)

  • 41. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Wolfram G; Keller C; Kilani C; Zöllner N
    Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug therapy for hyperlipidemia.
    Franklin FA; Margolis S
    Cardiovasc Clin; 1984; 14(3):265-84. PubMed ID: 6722855
    [No Abstract]   [Full Text] [Related]  

  • 43. [Effect of tiadenol in prolonged therapy of hyperlipoproteinemias (type IIa-IIb)].
    Rouffy J
    Therapie; 1975; 30(6):815-23. PubMed ID: 785682
    [No Abstract]   [Full Text] [Related]  

  • 44. [The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
    Forti N; Dereviacki BE; Giannini SD
    Arq Bras Cardiol; 1988 Jul; 51(1):49-53. PubMed ID: 3073736
    [No Abstract]   [Full Text] [Related]  

  • 45. [Hypolipemic effects of 1-10(hydroxy-2 ethylthio) decane (LL1558), based on 77 cases of essential hyperlipidemia].
    Rouffy J; Loeper J
    Therapie; 1972; 27(3):433-44. PubMed ID: 4570211
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hyperlipiemia and its therapy by clofibrate].
    Nakano M; Nakamura Y
    Iryo; 1969 Dec; 23(12):1473-8. PubMed ID: 5381198
    [No Abstract]   [Full Text] [Related]  

  • 47. [Controversies and advances in the treatment of hyperlipidemias].
    Reza-Albarrán A; Aguilar-Salinas CA
    Gac Med Mex; 1998; 134(2):253-6. PubMed ID: 9619005
    [No Abstract]   [Full Text] [Related]  

  • 48. [The management of hyperlipoproteinemia with Liproreduct].
    Fenster R
    Ther Ggw; 1974 May; 113(5):813-24. PubMed ID: 4603893
    [No Abstract]   [Full Text] [Related]  

  • 49. [Drug therapy of hyperlipidemias].
    Wolfram G
    Wien Med Wochenschr; 1981; 131(13-14):333-8. PubMed ID: 7281700
    [No Abstract]   [Full Text] [Related]  

  • 50. Preliminary observations on the effect of gemfibrozil on the excretion of faecal bile acids.
    Baird IM; Lewis B; Hill JM
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):112-4. PubMed ID: 1019150
    [No Abstract]   [Full Text] [Related]  

  • 51. [Clinical and biological study of a new vascular protective agent and hypolipemic agent, pyridoxine para-chloro-phénoxy-isobutyrate. (Claresan)].
    Fourrier A; Mouton Y
    Lille Med; 1974 Apr; 19(4 Suppl 11):532-7. PubMed ID: 4612283
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyperlipidemia: reducing the chances of cardiovascular disease.
    Nash DT
    Geriatrics; 1984 Jul; 39(7):99-100, 103-4,108-9 passim. PubMed ID: 6588017
    [No Abstract]   [Full Text] [Related]  

  • 53. [Hyperlipemia and pancreatitis].
    Carrillo Penso N; Carrasquero O; Medina JA
    G E N; 1981; 35(1-2):15-27. PubMed ID: 6816659
    [No Abstract]   [Full Text] [Related]  

  • 54. [The effect of gemfibrocil on serum lipids and lipoproteins in patients with hyperlipoproteinemia].
    Weisweiler P; Neureuther G; Schwandt P
    Verh Dtsch Ges Inn Med; 1978; (84):1160-3. PubMed ID: 741916
    [No Abstract]   [Full Text] [Related]  

  • 55. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy of hyperlipemias with lipolytic drugs].
    Jover Sanz E; Paradinas Jiménez C; Corporales López L; Martínez Robles JV
    Rev Clin Esp; 1974 Jun; 133(5):447-50. PubMed ID: 4428087
    [No Abstract]   [Full Text] [Related]  

  • 57. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 58. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of gemfibrozil on lipolysis in dogs in vivo.
    Riemersma RA; Oliver MF
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):107-8. PubMed ID: 1019148
    [No Abstract]   [Full Text] [Related]  

  • 60. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
    Tapounet R; Marti Ragué I
    Drugs Exp Clin Res; 1987; 13(7):447-50. PubMed ID: 3652931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.